Thrombolysis remains the only beneficial therapy for @entity385 , but is restricted to a short therapeutic window following the @entity1188 . Currently research is focusing on spontaneous regenerative processes during the sub-acute and chronic phase. Angiogenesis, the formation of new blood vessels from pre-existing ones, was observed in @entity64 @entity1 , correlates with longer survival and positively affects the formation of new neurons. Angiogenesis takes place in the border zones of the @entity1188 , but further insight into the temporal profile is needed to fully apprehend its therapeutic potential and its relevance for neurogenesis and functional recovery. Angiogenesis is a multistep process, involving extracellular matrix degradation, endothelial cell proliferation, and, finally, new vessel formation. Interaction between vascular endothelial growth factor and its receptor 2 ( @entity11132 ) plays a central role in these angiogenic signaling cascades. In the present study we investigated non-invasively the dynamics of @entity11132 expression following @entity2806 in a @entity19 model of @entity2500 ( @entity2500 ). We used a transgenic @entity19 expressing firefly luciferase under the control of the @entity11132 promotor to non-invasively elucidate the temporal profile of @entity11132 expression after @entity64 as a biomarker for @entity1611 / @entity11132 signaling. We measured each animal repetitively up to 2 weeks after @entity64 and found increased @entity11132 expression starting 3 days after the insult with peak values at 7 days. These were paralleled by increased @entity11132 protein levels and increased vascular volume in peri- @entity1188 areas at 14 days after the @entity1188 , indicating that signaling via @entity11132 leads to successful vascular remodeling. This study describes @entity11132 -related signaling is active at least up to 2 weeks after the @entity1188 and results in increased vascular volume. Further, this study presents a novel strategy for the non-invasive evaluation of angiogenesis-based therapies.

In vivo bioluminescence imaging of vascular remodeling after XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity11132 :: ('16542(Tax:10090)', 'Gene') :: ['VEGFR2'] @entity64 :: ('MESH:D020521', 'Disease') :: ['stroke'] @entity2806 :: ('MESH:D002545', 'Disease') :: ['cerebral ischemia'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity2500 :: ('MESH:D020244', 'Disease') :: ['MCAO', 'middle cerebral artery occlusion'] @entity1188 :: ('MESH:D007238', 'Disease') :: ['infarct'] @entity1611 :: ('22339(Tax:10090)', 'Gene') :: ['VEGF'] @entity385 :: ('MESH:D002544', 'Disease') :: ['ischemic stroke']
@entity64 :: (MESH:D020521,Disease) :: ['stroke']
